Monsanto (MON), which reported its earnings on January 4, 2018, has risen 2.1%. It’s awaiting a merger with Bayer, which continues to be delayed due to anti-trust concerns from regulators in the European Union and other regions. On February 7, 2018, the merger received approval from Brazilian antitrust regulators.
Let’s look now at analysts’ ratings for the stock.
As of February 22, 2018, the consensus mean rating for Monsanto from 18 analysts surveyed by Reuters was 2.6 with an overall “hold” recommendation for the next 12-month period. The rating was unchanged from January and could stay that way until the merger happens.
Of those 18 analysts, only two have a “strong buy” recommendation for the stock, while four have a “buy” recommendation for the next 12-month period.
Twelve analysts have a “hold” recommendation, and none of them have rated it a “sell.”
The current mean price target for Monsanto is $125.80, which is the same as the previous month. Its median price target is $128, which is Bayer’s acquisition price.
Both the mean and median price targets are higher than its price of $120.40 at the close of trading on February 22.
Next, let’s take a look at FMC’s (FMC) ratings and targets.